Laboratory Medicine ›› 2024, Vol. 39 ›› Issue (1): 47-52.DOI: 10.3969/j.issn.1673-8640.2024.01.009
Previous Articles Next Articles
WANG Yanyan1, WANG Junrui1, ZHENG Wenqi1, LAN Haixia2, GUO Sufang1()
Received:
2022-10-19
Revised:
2023-05-16
Online:
2024-01-30
Published:
2024-03-04
CLC Number:
WANG Yanyan, WANG Junrui, ZHENG Wenqi, LAN Haixia, GUO Sufang. Drug resistance of Bacteroides isolated from clinic and characteristics of Bacteroides fragilis bft genotyping[J]. Laboratory Medicine, 2024, 39(1): 47-52.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2024.01.009
基因 | 引物序列(5'~3') | 产物长度/bp |
---|---|---|
bft | F:GGATACATCAGCTGGGTTGTAG | |
R:GCGAACTCGGTTTATGCAGT | 296 | |
bft-1 | F:TCTTTTGAATTATCCGTATGCTC | |
R:CTTGGGATAATAAAATCTTAGGGATG | 196 | |
bft-2 | F:ATTTTTAGCGATTCTATACATGTTCTC | |
R:GGGCATATATTGGGTGCTAGG | 114 | |
bft-3 | F:TGGATCATCCGCATGGTTA | |
R:TTTGGGCATATCTTGGCTCA | 148 |
基因 | 引物序列(5'~3') | 产物长度/bp |
---|---|---|
bft | F:GGATACATCAGCTGGGTTGTAG | |
R:GCGAACTCGGTTTATGCAGT | 296 | |
bft-1 | F:TCTTTTGAATTATCCGTATGCTC | |
R:CTTGGGATAATAAAATCTTAGGGATG | 196 | |
bft-2 | F:ATTTTTAGCGATTCTATACATGTTCTC | |
R:GGGCATATATTGGGTGCTAGG | 114 | |
bft-3 | F:TGGATCATCCGCATGGTTA | |
R:TTTGGGCATATCTTGGCTCA | 148 |
样本类型 | 脆弱拟杆菌 | 多形拟杆菌 | 卵形拟杆菌 | 普通拟杆菌 | 其他拟杆菌 | 拟杆菌属 |
---|---|---|---|---|---|---|
腹腔脓液 | 91 | 20 | 9 | 6 | 4 | 130 |
口腔脓液 | 0 | 2 | 0 | 1 | 0 | 3 |
生殖道脓液 | 2 | 1 | 0 | 0 | 0 | 3 |
头部脓液 | 1 | 1 | 0 | 0 | 0 | 2 |
肢端脓液 | 2 | 0 | 0 | 0 | 0 | 2 |
血液 | 4 | 1 | 0 | 1 | 1 | 7 |
合计 | 100 | 25 | 9 | 8 | 5 | 147 |
样本类型 | 脆弱拟杆菌 | 多形拟杆菌 | 卵形拟杆菌 | 普通拟杆菌 | 其他拟杆菌 | 拟杆菌属 |
---|---|---|---|---|---|---|
腹腔脓液 | 91 | 20 | 9 | 6 | 4 | 130 |
口腔脓液 | 0 | 2 | 0 | 1 | 0 | 3 |
生殖道脓液 | 2 | 1 | 0 | 0 | 0 | 3 |
头部脓液 | 1 | 1 | 0 | 0 | 0 | 2 |
肢端脓液 | 2 | 0 | 0 | 0 | 0 | 2 |
血液 | 4 | 1 | 0 | 1 | 1 | 7 |
合计 | 100 | 25 | 9 | 8 | 5 | 147 |
抗菌药物 | 敏感/[%(株/株)] | 中介/[%(株/株)] | 耐药/[%(株/株)] |
---|---|---|---|
拟杆菌属 | |||
甲硝唑 | 94.6(139/147) | 0.7(1/147) | 4.7(7/147) |
哌拉西林-他唑巴坦 | 93.9(119/147) | 1.4(2/147) | 6.8(10/147) |
头孢西丁 | 85.0(125/147) | 11.6(17/147) | 3.4(5/147) |
哌拉西林 | 82.3(121/147) | 1.4(2/147) | 16.3(24/147) |
亚胺培南 | 79.6(117/147) | 6.8(10/147) | 13.6(20/147) |
氨苄西林-舒巴坦 | 68.7(101/147) | 6.8(10/147) | 24.5(36/147) |
克林霉素 | 19.7(29/147) | 1.4(2/147) | 78.9(116/147) |
抗菌药物 | 敏感/[%(株/株)] | 中介/[%(株/株)] | 耐药/[%(株/株)] |
脆弱拟杆菌 | |||
甲硝唑 | 93.0(93/100) | 1.0(1/100) | 6.0(6/100) |
哌拉西林-他唑巴坦 | 90.0(90/100) | 1.0(1/100) | 9.0(9/100) |
哌拉西林 | 87.0(87/100) | 0(0/100) | 13.0(13/100) |
头孢西丁 | 86.0(84/100) | 13.0(13/100) | 1.0(1/100) |
亚胺培南 | 79.0(79/100) | 5.0(5/100) | 16.0(16/100) |
氨苄西林-舒巴坦 | 66.0(66/100) | 6.0(6/100) | 28.0(28/100) |
克林霉素 | 15.0(15/100) | 0(0/100) | 85.0(85/100) |
其他拟杆菌 | |||
甲硝唑 | 97.9(46/47) | 0(0/47) | 2.1(1/47) |
哌拉西林-他唑巴坦 | 95.7(45/47) | 2.1(1/47) | 2.1(1/47) |
亚胺培南 | 87.2(41/47) | 10.6(5/47) | 2.1(1/47) |
头孢西丁 | 83.0(39/47) | 8.5(4/47) | 8.5(4/47) |
氨苄西林-舒巴坦 | 74.5(35/47) | 8.5(4/47) | 17.0(8/47) |
哌拉西林 | 72.3(34/47) | 4.3(2/47) | 23.4(11/47) |
克林霉素 | 29.8(14/47) | 4.3(2/47) | 66.0(31/47) |
抗菌药物 | 敏感/[%(株/株)] | 中介/[%(株/株)] | 耐药/[%(株/株)] |
---|---|---|---|
拟杆菌属 | |||
甲硝唑 | 94.6(139/147) | 0.7(1/147) | 4.7(7/147) |
哌拉西林-他唑巴坦 | 93.9(119/147) | 1.4(2/147) | 6.8(10/147) |
头孢西丁 | 85.0(125/147) | 11.6(17/147) | 3.4(5/147) |
哌拉西林 | 82.3(121/147) | 1.4(2/147) | 16.3(24/147) |
亚胺培南 | 79.6(117/147) | 6.8(10/147) | 13.6(20/147) |
氨苄西林-舒巴坦 | 68.7(101/147) | 6.8(10/147) | 24.5(36/147) |
克林霉素 | 19.7(29/147) | 1.4(2/147) | 78.9(116/147) |
抗菌药物 | 敏感/[%(株/株)] | 中介/[%(株/株)] | 耐药/[%(株/株)] |
脆弱拟杆菌 | |||
甲硝唑 | 93.0(93/100) | 1.0(1/100) | 6.0(6/100) |
哌拉西林-他唑巴坦 | 90.0(90/100) | 1.0(1/100) | 9.0(9/100) |
哌拉西林 | 87.0(87/100) | 0(0/100) | 13.0(13/100) |
头孢西丁 | 86.0(84/100) | 13.0(13/100) | 1.0(1/100) |
亚胺培南 | 79.0(79/100) | 5.0(5/100) | 16.0(16/100) |
氨苄西林-舒巴坦 | 66.0(66/100) | 6.0(6/100) | 28.0(28/100) |
克林霉素 | 15.0(15/100) | 0(0/100) | 85.0(85/100) |
其他拟杆菌 | |||
甲硝唑 | 97.9(46/47) | 0(0/47) | 2.1(1/47) |
哌拉西林-他唑巴坦 | 95.7(45/47) | 2.1(1/47) | 2.1(1/47) |
亚胺培南 | 87.2(41/47) | 10.6(5/47) | 2.1(1/47) |
头孢西丁 | 83.0(39/47) | 8.5(4/47) | 8.5(4/47) |
氨苄西林-舒巴坦 | 74.5(35/47) | 8.5(4/47) | 17.0(8/47) |
哌拉西林 | 72.3(34/47) | 4.3(2/47) | 23.4(11/47) |
克林霉素 | 29.8(14/47) | 4.3(2/47) | 66.0(31/47) |
样本类型 | 分离菌株 | bft阳性 | bft-1阳性 | bft-2阳性 | bft-3阳性 |
---|---|---|---|---|---|
腹部样本 | 91(91.0) | 33(36.3) | 23(30.8) | 10(11.0) | 0(0) |
非腹部样本 | 9(9.0) | 5(55.6) | 5(55.6) | 0(0) | 0(0) |
合计 | 100(100.0) | 38(38.0) | 28(28.0) | 10(10.0) | 0(0) |
样本类型 | 分离菌株 | bft阳性 | bft-1阳性 | bft-2阳性 | bft-3阳性 |
---|---|---|---|---|---|
腹部样本 | 91(91.0) | 33(36.3) | 23(30.8) | 10(11.0) | 0(0) |
非腹部样本 | 9(9.0) | 5(55.6) | 5(55.6) | 0(0) | 0(0) |
合计 | 100(100.0) | 38(38.0) | 28(28.0) | 10(10.0) | 0(0) |
[1] | SÁRVÁRI K P, RÁCZ N B, BURIÁN K. Epidemiology and antibiotic susceptibility in anaerobic bacteraemia:a 15-year retrospective study in South-Eastern Hungary[J]. Infect Dis(Lond), 2022, 54(1):16-25. |
[2] |
DI BELLA S, ANTONELLO R M, SANSON G, et al. Anaerobic bloodstream infections in Italy(ITANAEROBY):a 5-year retrospective nationwide survey[J]. Anaerobe, 2022, 75:102583.
DOI URL |
[3] |
HASTEY C J, BOYD H, SCHUETZ A N, et al. Changes in the antibiotic susceptibility of anaerobic bacteria from 2007-2009 to 2010-2012 based on the CLSI methodology[J]. Anaerobe, 2016, 42(11):27-30.
DOI URL |
[4] | SÁRVÁRI K P, SÓKI J, KRISTÓF K, et al. A multicentre survey of the antibiotic susceptibility of clinical Bacteroides species from Hungary[J]. Infect Dis(Lond), 2018, 50(5):372-380. |
[5] |
JAMAL W, KHODAKHAST F B, ALAZMI A, et al. Prevalence and antimicrobial susceptibility of enterotoxigenic extra-intestinal Bacteroides fragilis among 13-year collection of isolates in Kuwait[J]. BMC Microbiol, 2020, 20(1):14.
DOI |
[6] |
COPSEY-MAWER S, HUGHES H, SCOTFORD S, et al. UK bacteroides species surveillance survey:change in antimicrobial resistance over 16 years(2000-2016)[J]. Anaerobe, 2021, 72:102447.
DOI URL |
[7] |
SHAO X, SUN S, ZHOU Y, et al. Bacteroides fragilis restricts colitis-associated cancer via negative regulation of the NLRP3 axis[J]. Cancer Lett, 2021, 523(28):170-181.
DOI URL |
[8] |
CHEN C Y, LIN M J, YANG W C, et al. Clinical spectrum of intra-abdominal abscesses in children admitted to the pediatric emergency department[J]. J Microbiol Immunol Infect, 2020, 53(2):283-291.
DOI URL |
[9] |
CHO Y, MINAMI K, KASAI M, et al. Infective endocarditis due to multiple species of anaerobes following tricuspid valve replacement[J]. J Microbiol Immunol Infect, 2017, 50(5):733-734.
DOI URL |
[10] |
AL BENWAN K, AL MULLA A, ROTIMI V O. A study of the microbiology of breast abscess in a teaching hospital in Kuwait[J]. Med Princ Pract, 2011, 20(5):422-426.
DOI PMID |
[11] |
JASEMI S, EMANEINI M, FAZELI M S, et al. Toxigenic and non-toxigenic patterns Ⅰ,Ⅱ and Ⅲ and biofilm-forming ability in Bacteroides fragilis strains isolated from patients diagnosed with colorectal cancer[J]. Gut Pathog, 2020, 12:28.
DOI |
[12] |
ZAMANI S, TASLIMI R, SARABI A, et al. Enterotoxigenic bacteroides fragilis:a possible etiological candidate for bacterially-induced colorectal precancerous and cancerous lesions[J]. Front Cell Infect Microbiol, 2020, 9:449.
DOI URL |
[13] |
BOLEIJ A, HECHENBLEIKNER E M, GOODWIN A C, et al. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients[J]. Clin Infect Dis, 2015, 60(2):208-215.
DOI URL |
[14] | Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. M100-S32,CLSI, 2022. |
[15] |
TOPRAK N U, YAGCI A, GULLUOGLU B M, et al. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer[J]. Clin Microbiol Infect, 2006, 12(8):782-786.
DOI URL |
[16] |
HO P L, YAU C Y, HO L Y, et al. Antimicrobial susceptibility of Bacteroides fragilis group organisms in Hong Kong by the tentative EUCAST disc diffusion method[J]. Anaerobe, 2017, 47(10):51-56.
DOI URL |
[17] |
TREVIÑO M, ARESES P, PEÑALVER M D, et al. Susceptibility trends of Bacteroides fragilis group and characterisation of carbapenemase-producing strains by automated REP-PCR and MALDI TOF[J]. Anaerobe, 2012, 18(1):37-43.
DOI URL |
[18] |
JAMAL W, KHODAKHAST F B, ALAZMI A, et al. Prevalence and antimicrobial susceptibility of enterotoxigenic extra-intestinal Bacteroides fragilis among 13-year collection of isolates in Kuwait[J]. BMC Microbiology, 2020, 20(1):14.
DOI |
[19] |
SNYDMAN D R, JACOBUS N V, MCDERMOTT L A, et al. Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009[J]. Anaerobe, 2017, 43:21-26.
DOI URL |
[20] |
RODLOFF A C, DOWZICKY M J. In vitro activity of tigecycline and comparators against a European collection of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial(T. E. S. T.)2010-2016[J]. Anaerobe, 2018, 51:78-88.
DOI URL |
[21] |
YUNOKI T, MATSUMURA Y, YAMAMOTO M, et al. Genetic identification and antimicrobial susceptibility of clinically isolated anaerobic bacteria:a prospective multicenter surveillance study in Japan[J]. Anaerobe, 2017, 48:215-223.
DOI URL |
[22] |
NAGY E, URBÁN E, NORD C E. Antimicrobial susceptibility of Bacteroides fragilis,group isolates in Europe:20 years of experience[J]. Clin Microbiol Infect, 2011, 17(3):371-379.
DOI URL |
[23] | KARLOWSKY J A, WALKTY A J, ADAM H J, et al. Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011:CANWARD Surveillance Study[J]. Antimicrob Chemother, 2012, 56(2):1247-1252. |
[24] |
HANSEN K C M, SCHWENSEN S A F, HENRIKSEN D P, et al. Antimicrobial resistance in the Bacteroides fragilis group in faecal samples from patients receiving broad-spectrum antibiotics[J]. Anaerobe, 2017, 47:79-85.
DOI URL |
[25] |
VISHWANATH S, SHENOY P A, CHAWLA K. Antimicrobial resistance profile and nim gene detection among Bacteroides fragilis group isolates in a university hospital in South India[J]. J Glob Infect Dis, 2019, 11(2):59-62.
DOI URL |
[26] |
WANG Y, CHEN X F, XIE X L, et al. Evaluation of VITEK MS,Clin-ToF-II MS,Autof MS 1000 and VITEK 2 ANC card for identification of Bacteroides fragilis group isolates and antimicrobial susceptibilities of these isolates in a Chinese university hospital[J]. J Microbiol Immunol Infect, 2019, 52(3):456-464.
DOI URL |
[27] |
WEXLER H M. Bacteroides:the good,the bad and the nitty-gritty[J]. Clin Microbiol Rev, 2007, 20(4):593-621.
DOI URL |
[28] |
KIERZKOWSKA M, MAJEWSKA A, SZYMANEK-MAJCHRZAK K, et al. The presence of antibiotic resistance genes and bft genes as well as antibiotic susceptibility testing of Bacteroides fragilis strains isolated from inpatients of infant Jesus teaching hospital,Warsaw during 2007-2012[J]. Anaerobe, 2019, 56:109-115.
DOI URL |
[29] |
KATO N, KATO H, WATANABE K, et al. Association of enterotoxigenic Bacteroides fragilis with bacteremia[J]. Clin Infect Dis, 1996, 23(Suppl 1):S83-S86.
DOI URL |
[30] |
CHUNG G T, FRANCO A A, WU S, et al. Identification of a third metalloprotease toxin gene in extraintestinal isolates of Bacteroides fragilis[J]. Infect Immun, 1999, 67(9):4945-4951.
DOI URL |
[31] |
MUNDY L M, SEARS C L. Detection of toxin production by Bacteroides fragilis:assay development and screening of extraintestinal clinical isolates[J]. Clin Infect Dis, 1996, 23(2):269-276.
DOI URL |
[32] |
SÁRVÁRI K P, SÓKI J, IVÁN M, et al. Detection of enterotoxin and protease genes among Hungarian clinical Bacteroides fragilis isolates[J]. Anaerobe, 2017, 48:98-102.
DOI URL |
[1] | WANG Chao, ZHAO Yu. Research progress on formation mechanism and eradication strategy of bacterial persisters [J]. Laboratory Medicine, 2023, 38(8): 790-795. |
[2] | ZHU Yurong, ZHANG Dan, HE Yaxing, LI Jingjing, HUANG Jing, LI Ting, LIU Peng, LIU Ronghua. Classification and epidemiology characteristics of Klebsiella pneumoniae isolated from clinic [J]. Laboratory Medicine, 2023, 38(5): 435-440. |
[3] | FANG Yongmei, ZHANG Yan, XU Xueying, ZHONG Feng. Correlation of Staphylococcus aureus drug resistance with drug resistance genes and virulence genes [J]. Laboratory Medicine, 2023, 38(4): 357-361. |
[4] | WANG Jiawei, ZHU Weinan, CHEN Yingying, JI Ping, WANG Ying. Clinical characteristics,molecular typing and drug resistance genes of carbapenem-resistant Klebsiella pneumoniae isolated from blood culturing [J]. Laboratory Medicine, 2023, 38(4): 362-367. |
[5] | REN Yanfei, ZHANG Min, YANG Tao, LI Rongkai, LIANG Xin. Analysis of pathogenic epidemiology of patients with lower respiratory tract infection in respiratory intensive care unit [J]. Laboratory Medicine, 2023, 38(2): 157-162. |
[6] | DENG Chen, DAI Jiaze, QIU Lihong, SHEN Weiting, CAI Mufa, LUO Wenying. Molecular epidemic characteristics of hypervirulent Klebsiella pneumoniae in Zhanjiang [J]. Laboratory Medicine, 2023, 38(11): 1026-1031. |
[7] | RU Haohao, CHEN Lianyong, YANG Xing, CHEN Tao, YAN Shuangqun, XU Lin. Analysis of rifampicin resistance in Mycobacterium tuberculosis determined by Xpert MTB/RIF and phenotypic drug susceptibility test [J]. Laboratory Medicine, 2023, 38(11): 1032-1035. |
[8] | WANG Su, DING Li, JIANG Wenrong, MIAO Yingxin, ZHANG Yanmei, ZHAO Hu. Research progress on drug resistance and treatment strategies of hypervirulent Klebsiella pneumoniae [J]. Laboratory Medicine, 2023, 38(1): 81-86. |
[9] | HAO Jiahui, YANG Zehua. Research progress of bacterial integron determination methods [J]. Laboratory Medicine, 2022, 37(9): 887-891. |
[10] | LI Hua, WANG Weiliang, XIE Bei, YANG Yu, MENG Fanrong, WANG Nan, LIU Zhihui, ZHANG Yanbin. Feasibility of the determination of heterogeneous drug resistance to rifampicin in Mycobacterium tuberculosis by flow cytometry [J]. Laboratory Medicine, 2022, 37(6): 577-582. |
[11] | SUN Xiaodan, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Research progress on the role of estrogen receptor in osteosarcoma [J]. Laboratory Medicine, 2022, 37(4): 313-318. |
[12] | WANG Jianying, WANG Shanshan, ZHU Jun, HUANG Xiaochun, WAN Yuxiang, LIU Yun. Distribution and drug resistance of respiratory infection pathogens in patients with lung cancer after chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 356-359. |
[13] | SUN Ying, LI Yi, YAN Wenjuan, JING Nan, MA Bing. Analysis of drug resistance of rare CRE and clinical application of carbapenem screening test in Henan [J]. Laboratory Medicine, 2022, 37(2): 146-149. |
[14] | WANG Lixin, SU Yunfu, WANG Yi. Research progress on the drug resistance mechanism of clinical pathogens to fosfomycin [J]. Laboratory Medicine, 2022, 37(10): 993-997. |
[15] | WANG Jingjing, WU Linqing, CHEN Rushou, WANG Yufeng. Drug resistance genotype,transposon structure and MLSA of vancomycin-resistant Enterococcus [J]. Laboratory Medicine, 2021, 36(9): 891-895. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||